EZH2 and myeloid neoplasm: One preclinical study implicated EZH2 in the pathogenesis of a murine KMT2A-MLLT3 AML model, but generally, EZH2 does not seem to represent an important driver in the pathogenesis of myeloid neoplasms and is currently not considered a promising therapeutic target these diseases [46, 47].